CG Oncology (CGON) Change in Account Payables (2023 - 2026)

CG Oncology has reported Change in Account Payables for 4 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 1078.5% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $664000.0 (down 67.95% YoY), and the FY2025 full-year result was -$1.6 million, down 150.2% from the prior year.
• Change in Account Payables for Q1 2026 stood at $2.5 million, up from -$3.5 million in the prior quarter.
• The five-year high for Change in Account Payables was $2.5 million in Q1 2026, with the low at -$3.5 million in Q4 2025.
• Historically, Change in Account Payables has averaged $474230.8 across 4 years, with a median of $394000.0 in 2025.
• The largest YoY upside for Change in Account Payables was 15844.44% in 2024 against a maximum downside of 442.86% in 2024.
• CG Oncology's Change in Account Payables stood at $1.4 million in 2023, then surged by 76.63% to $2.4 million in 2024, then tumbled by 242.52% to -$3.5 million in 2025, then jumped by 172.49% to $2.5 million in 2026.
• The last three Change in Account Payables figures came in at $2.5 million (Q1 2026), -$3.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.